In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan

Hsiu Ping Chien, Ming Chih Yu, Tzong Fei Ong, Tao Ping Lin, Kwen Tay Luh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and purpose: To determine the in vitro activity of rifabutin against Mycobacterium tuberculosis (MTB) and the cross-resistance rate between rifampin and rifabutin. Methods:A total of 56 clinical isolates of MTB, including 23 multidrug-resistant (MDR) isolates and 33 susceptible isolates, were tested for susceptibility to rifampin and rifabutin using the absolute concentration method. The concentrations of drugs tested were 2.5 and 5 mg/mL for rifampin and 0.1, 0.5, 1, 2,5, 5, and 10 mg/mL for rifabutin. Results: All 33 MTB isolates that were susceptible to rifampin were also susceptible to rifabutin. None of the 23 MDR-MTB isolates were inhibited by rifabutin at a concentration of 0.1 mg/mL. Among these 23 MDR isolates, three were susceptible to rifabutin at concentrations ≥ 0.5 mg/mL, six were susceptible to rifabutin at concentrations ≥ 5 mg/mL, 18 were susceptible to rifabutin at concentrations ≥ 10 mg/mL and five were not inhibited at any of the concentrations tested. The cross-resistance rate between rifampin and rifabutin was 87%. Conclusions: Our results indicate that the in vitro activity of rifabutin against drug- susceptible MTB isolates is greater than that of rifampin. For MDR-MTB isolates, the cross-resistance is high between rifampin and rifabutin.

Original languageEnglish
Pages (from-to)408-411
Number of pages4
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume99
Issue number5
Publication statusPublished - May 2000
Externally publishedYes

Fingerprint

Rifabutin
Rifampin
Taiwan
Mycobacterium tuberculosis
Multidrug-Resistant Tuberculosis
In Vitro Techniques
Pharmaceutical Preparations

Keywords

  • Multidrug resistance
  • Mycobacterium tuberculosis
  • Rifabutin
  • Rifampin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. / Chien, Hsiu Ping; Yu, Ming Chih; Ong, Tzong Fei; Lin, Tao Ping; Luh, Kwen Tay.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 99, No. 5, 05.2000, p. 408-411.

Research output: Contribution to journalArticle

@article{122017116db14c6ba0e3402978d4d3f5,
title = "In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan",
abstract = "Background and purpose: To determine the in vitro activity of rifabutin against Mycobacterium tuberculosis (MTB) and the cross-resistance rate between rifampin and rifabutin. Methods:A total of 56 clinical isolates of MTB, including 23 multidrug-resistant (MDR) isolates and 33 susceptible isolates, were tested for susceptibility to rifampin and rifabutin using the absolute concentration method. The concentrations of drugs tested were 2.5 and 5 mg/mL for rifampin and 0.1, 0.5, 1, 2,5, 5, and 10 mg/mL for rifabutin. Results: All 33 MTB isolates that were susceptible to rifampin were also susceptible to rifabutin. None of the 23 MDR-MTB isolates were inhibited by rifabutin at a concentration of 0.1 mg/mL. Among these 23 MDR isolates, three were susceptible to rifabutin at concentrations ≥ 0.5 mg/mL, six were susceptible to rifabutin at concentrations ≥ 5 mg/mL, 18 were susceptible to rifabutin at concentrations ≥ 10 mg/mL and five were not inhibited at any of the concentrations tested. The cross-resistance rate between rifampin and rifabutin was 87{\%}. Conclusions: Our results indicate that the in vitro activity of rifabutin against drug- susceptible MTB isolates is greater than that of rifampin. For MDR-MTB isolates, the cross-resistance is high between rifampin and rifabutin.",
keywords = "Multidrug resistance, Mycobacterium tuberculosis, Rifabutin, Rifampin",
author = "Chien, {Hsiu Ping} and Yu, {Ming Chih} and Ong, {Tzong Fei} and Lin, {Tao Ping} and Luh, {Kwen Tay}",
year = "2000",
month = "5",
language = "English",
volume = "99",
pages = "408--411",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan

AU - Chien, Hsiu Ping

AU - Yu, Ming Chih

AU - Ong, Tzong Fei

AU - Lin, Tao Ping

AU - Luh, Kwen Tay

PY - 2000/5

Y1 - 2000/5

N2 - Background and purpose: To determine the in vitro activity of rifabutin against Mycobacterium tuberculosis (MTB) and the cross-resistance rate between rifampin and rifabutin. Methods:A total of 56 clinical isolates of MTB, including 23 multidrug-resistant (MDR) isolates and 33 susceptible isolates, were tested for susceptibility to rifampin and rifabutin using the absolute concentration method. The concentrations of drugs tested were 2.5 and 5 mg/mL for rifampin and 0.1, 0.5, 1, 2,5, 5, and 10 mg/mL for rifabutin. Results: All 33 MTB isolates that were susceptible to rifampin were also susceptible to rifabutin. None of the 23 MDR-MTB isolates were inhibited by rifabutin at a concentration of 0.1 mg/mL. Among these 23 MDR isolates, three were susceptible to rifabutin at concentrations ≥ 0.5 mg/mL, six were susceptible to rifabutin at concentrations ≥ 5 mg/mL, 18 were susceptible to rifabutin at concentrations ≥ 10 mg/mL and five were not inhibited at any of the concentrations tested. The cross-resistance rate between rifampin and rifabutin was 87%. Conclusions: Our results indicate that the in vitro activity of rifabutin against drug- susceptible MTB isolates is greater than that of rifampin. For MDR-MTB isolates, the cross-resistance is high between rifampin and rifabutin.

AB - Background and purpose: To determine the in vitro activity of rifabutin against Mycobacterium tuberculosis (MTB) and the cross-resistance rate between rifampin and rifabutin. Methods:A total of 56 clinical isolates of MTB, including 23 multidrug-resistant (MDR) isolates and 33 susceptible isolates, were tested for susceptibility to rifampin and rifabutin using the absolute concentration method. The concentrations of drugs tested were 2.5 and 5 mg/mL for rifampin and 0.1, 0.5, 1, 2,5, 5, and 10 mg/mL for rifabutin. Results: All 33 MTB isolates that were susceptible to rifampin were also susceptible to rifabutin. None of the 23 MDR-MTB isolates were inhibited by rifabutin at a concentration of 0.1 mg/mL. Among these 23 MDR isolates, three were susceptible to rifabutin at concentrations ≥ 0.5 mg/mL, six were susceptible to rifabutin at concentrations ≥ 5 mg/mL, 18 were susceptible to rifabutin at concentrations ≥ 10 mg/mL and five were not inhibited at any of the concentrations tested. The cross-resistance rate between rifampin and rifabutin was 87%. Conclusions: Our results indicate that the in vitro activity of rifabutin against drug- susceptible MTB isolates is greater than that of rifampin. For MDR-MTB isolates, the cross-resistance is high between rifampin and rifabutin.

KW - Multidrug resistance

KW - Mycobacterium tuberculosis

KW - Rifabutin

KW - Rifampin

UR - http://www.scopus.com/inward/record.url?scp=0034083414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034083414&partnerID=8YFLogxK

M3 - Article

C2 - 10870331

AN - SCOPUS:0034083414

VL - 99

SP - 408

EP - 411

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 5

ER -